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Abstract
Introduction: Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-
positive gastrointestinal stromal tumors. However, it is unknown whether patients who previously received
adjuvant imatinib therapy will respond to imatinib rechallenge as treatment for recurrent disease. Here we present
the first report documenting the benefits of imatinib rechallenge in a patient previously exposed to imatinib
during adjuvant treatment.
Case presentation: A 51-year-old Asian woman with a wedge-resected primary gastric gastrointestinal stromal
tumor at high risk of relapse underwent two years of adjuvant treatment with imatinib. Only 10 months after the
completion of adjuvant imatinib treatment, a computed tomography scan revealed gastrointestinal stromal tumor
recurrence in this patient, with multiple peritoneal nodules in the upper abdomen being detected. Our patient was
rechallenged with imatinib 400 mg/day and had a partial response after one month of treatment. Imatinib
rechallenge was well tolerated by our patient; the only adverse events she experienced were grade 1 edema,
anemia and fatigue. Our patient maintained a partial response two years and six months after the imatinib
rechallenge. However, computed tomography scans three months later showed that our patient had disease
progression.
Conclusions: This case report demonstrates that a patient with a gastrointestinal stromal tumor who had
previously received adjuvant imatinib therapy responded to imatinib rechallenge as treatment for her recurrent
disease. These results indicate that imatinib sensitivity can be maintained in a patient with previous exposure to
adjuvant imatinib therapy.
Introduction
Gastrointestinal stromal tumors (GIST) are the most com-
mon mesenchymal tumors of the gastrointestinal tract.
These tumors are characterized by activating mutations of
either receptor tyrosine kinase KIT or, less commonly, pla-
telet-derived growth factor receptor a (PDGFRa)[ 1 ] .I m a -
tinib mesylate, an oral selective inhibitor of KIT and
PDGFRa, is approved for the treatment of adult patients
with unresectable and/or metastatic KIT-positive (KIT+)
GIST. It is also indicated for the adjuvant treatment of
adult patients following resection of GIST [2]. Current
guidelines [3,4] recommend adjuvant treatment with ima-
tinib for at least one year and the use of risk assessment
systems based on the main variables of mitotic rate, tumor
size, tumor site and tumor rupture to guide patient selec-
tion for adjuvant imatinib therapy. This recommendation
is based on results from the pivotal American College of
Surgeons Oncology Group (ACOSOG) Z9001 trial. This
trial demonstrated a significant one-year recurrence-free
survival (RFS) benefit for adjuvant imatinib versus placebo
after the treatments were given for one year in patients at
various levels of risk for recurrence [5]. However, optimal
duration of adjuvant imatinib has not yet been deter-
mined, and a longer course of therapy may be needed for
patients at higher risk of recurrence.
A recent Korean, single-arm, Phase II study evaluated
the efficacy of two years of adjuvant imatinib treatment
in GIST patients with KIT exon 11 mutations who are at
high risk of relapse following surgical resection of the
Correspondence: ykkang@amc.seoul.kr
Department of Oncology, University of Ulsan College of Medicine, Asan
Medical Center, Seoul, Korea
Kang Journal of Medical Case Reports 2011, 5:504
http://www.jmedicalcasereports.com/content/5/1/504 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Kang; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.primary GIST [6]. The study showed a two-year RFS rate
of 93.3%, which compared favorably with an RFS of 73%
at two years after one year of adjuvant imatinib therapy
in a similar patient population, reported in another
single-arm, Phase II study (ACOSOG Z9000) [7]. These
results suggest that a longer duration of adjuvant imati-
nib treatment may improve the RFS of patients with KIT
+ GIST after surgery. However, it is unclear whether this
improvement in RFS will ultimately extend overall survi-
val (OS) in these patients. One of the critical factors that
will affect OS improvement is the effect of adjuvant ther-
apy on the efficacy of imatinib rechallenge for treating
recurrent disease. Although the results of another trial
(BFR14) showed that most patients with progressive
metastatic GIST were able to respond to imatinib rechal-
lenge after treatment interruption [8], it remains to be
determined whether imatinib sensitivity could also be
maintained after completion of adjuvant treatment. Here,
we report on a patient who responded to rechallenge
with imatinib after experiencing recurrence subsequent
to completion of two years of adjuvant imatinib therapy.
Case presentation
A 51-year-old Asian woman diagnosed with a primary
gastric GIST underwent wedge resection, achieving com-
plete removal of the entire tumor with microscopic
examination of the margins showing no tumor cells (R0
margins). She was considered at high risk for recurrence
b a s e do nt h et u m o rs i z e( 8c m×7c m×3c m )a n dh i g h
mitotic rate (>50 mitoses per 50 high powered fields
(HPF)) of the excised GIST [9,10]. In addition, mutation
analysis showed that the tumor had KIT exon 11 dele-
tions, a genotype shown to be associated with adverse
outcomes after surgery [10]. As such, our patient was
enrolled in the aforementioned Korean Phase II trial of
adjuvant imatinib for patients with localized KIT exon
11-mutant GIST at high risk of relapse [6]. Our patient
was started on imatinib adjuvant treatment 400 mg/day
but developed a skin rash after three months; the rash
was successfully managed with a temporary (three-week)
dose interruption. Our patient was subsequently restarted
on imatinib 300 mg/day and resumed taking standard-
dose imatinib 400 mg/day after three months. She was
maintained, generally tolerated this dose and completed
the two-year adjuvant therapy regimen.
Ten months after stopping adjuvant imatinib treatment,
recurrence was detected in this patient, as computed
tomography (CT) scans revealed three gross peritoneal
nodules in her upper abdomen (Figure 1A and 1B). Our
patient was rechallenged with imatinib 400 mg/day as
first-line treatment for her recurrent or metastatic disease.
After one month of treatment, a partial response (PR) by
Response Evaluation Criteria In Solid Tumors was
observed; the three peritoneal nodules had decreased in
size from 31.4 mm, 15.3 mm and 22.1 mm (sum, 69 mm;
Figure 1A and 1B) to 17.1 mm, 9.2 mm and 12.4 mm,
respectively (sum, 39 mm; Figure 1C and 1D), represent-
ing a 43% decrease in size. Imatinib rechallenge was well
tolerated, as the only adverse events experienced by our
patient were grade 1 edema, anemia and fatigue. Our
patient maintained a stable PR for over two and a half
years after being rechallenged with imatinib treatment, as
evidenced by repeated CT scans. However, progression
was observed three months later; CT scans revealed that
the sum of two peritoneal nodules had increased in size by
50% since the last tumor assessment. Disease progression
was confronted through dose escalation to imatinib 800
mg/day. Our patient’s response to dose escalation will be
monitored closely during future follow-up visits.
Discussion
The results of this case report demonstrate that a GIST
patient who has undergone adjuvant imatinib therapy
responded when rechallenged with imatinib as a treatment
for her recurrent disease. These results suggest that sensi-
tivity to imatinib was not compromised by prior exposure
to adjuvant imatinib.
The Korean adjuvant Phase II study referred to in this
case report enrolled patients with resected primary GIST
possessing KIT exon 11 mutations at high risk of recur-
rence (mitotic rate ≥5 mitoses/50 HPF and tumor size ≥5
cm, or mitotic rate ≥10 mitoses/50 HPF, or tumor size
≥10 cm) [9,10]. Our previous retrospective study showed
t h a tt h ep r e s e n c eo fKIT mutations, along with a high
mitotic rate and larger tumor size, was an independent
risk factor for poor prognosis in patients with localized
GIST [10]. Because GIST harboring KIT exon 11 muta-
tions appeared to be more sensitive to imatinib treatment
than GIST of other genotypes in the metastatic setting
[11] and, shown more recently, in the adjuvant setting
[12], patients with KIT exon 11 mutations at high risk of
recurrence would be most likely to benefit from adjuvant
treatment with imatinib. The fact that some patients,
including our patient described in this case report, devel-
oped disease recurrence after stopping adjuvant therapy
suggests that two years of adjuvant imatinib treatment
may not be sufficient for eradicating residual GIST tumor
cells and preventing relapse in these high-risk patients.
Our patient’s residual tumor cells remained sensitive to
imatinib therapy, as evidenced by her good response to
subsequent imatinib rechallenge. However, it appears that
the sensitive residual tumor cells need to be continuously
suppressed with adjuvant imatinib therapy to prevent or
further delay disease recurrence. The question of how
long patients should be treated with adjuvant imatinib
remains. The Phase III study conducted by the Scandina-
vian Sarcoma Group (SSG) and the Sarcoma Group of the
Arbeitsgemeinschaft Internistische Onkologie (AIO;
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years of adjuvant imatinib treatment, compared with one
year of imatinib treatment, significantly improves RFS and
OS in GIST patients who have a high estimated risk of
recurrence after surgery [13]. This suggests that patients at
high risk of recurrence, such as our patient described in
this case report, should receive adjuvant imatinib treat-
ment for a minimum duration of three years. This is
reflected in the updated National Comprehensive Cancer
Network guidelines that, based on the results of the
SSGXVIII/AIO trial, recommend considering adjuvant
imatinib for at least 36 months for patients with high-risk
GIST [14].
Our patient in this case report remained progression-
free for two years and nine months, which is shorter than
the median progression-free survival (PFS) of approxi-
mately four years achieved in a Korean Phase II study of
patients with advanced GIST [15], but longer than the
median PFS of 18 to 20 months reported in other studies
of imatinib therapy for metastatic or recurrent GIST [16].
Although it is not feasible to compare the results of clini-
cal studies conducted in different patient populations at





Figure 1 CT scans of our patient before and after imatinib rechallenge. (A,B) Recurrent tumors (nodules) can be seen in the peritoneum of
our patient, who had received prior adjuvant imatinib treatment. (C,D) After one month of rechallenge with imatinib, our patient demonstrated
a partial response to imatinib treatment, with the nodule sizes decreasing by 43%.
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case report suggest that our patient maintained sensitivity
to imatinib even though she was previously exposed to
imatinib for two years in the adjuvant setting.
Conclusion
Rechallenge with imatinib may provide substantial clini-
cal benefit to patients with recurrent GIST after cessa-
tion of adjuvant imatinib therapy.
Consent
Written informed consent was obtained from our
patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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